ALEC
Price
$1.54
Change
+$0.13 (+9.22%)
Updated
Jun 6, 01:28 PM (EDT)
Capitalization
154.99M
55 days until earnings call
RGNX
Price
$9.56
Change
+$1.20 (+14.35%)
Updated
Jun 6, 02:42 PM (EDT)
Capitalization
417.84M
54 days until earnings call
Interact to see
Advertisement

ALEC vs RGNX

Header iconALEC vs RGNX Comparison
Open Charts ALEC vs RGNXBanner chart's image
Alector
Price$1.54
Change+$0.13 (+9.22%)
Volume$200
Capitalization154.99M
REGENXBIO
Price$9.56
Change+$1.20 (+14.35%)
Volume$1.33K
Capitalization417.84M
ALEC vs RGNX Comparison Chart
Loading...
ALEC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALEC vs. RGNX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a StrongBuy and RGNX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ALEC: $1.41 vs. RGNX: $8.33)
Brand notoriety: ALEC and RGNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALEC: 36% vs. RGNX: 228%
Market capitalization -- ALEC: $154.99M vs. RGNX: $417.84M
ALEC [@Biotechnology] is valued at $154.99M. RGNX’s [@Biotechnology] market capitalization is $417.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALEC’s FA Score shows that 0 FA rating(s) are green whileRGNX’s FA Score has 1 green FA rating(s).

  • ALEC’s FA Score: 0 green, 5 red.
  • RGNX’s FA Score: 1 green, 4 red.
According to our system of comparison, RGNX is a better buy in the long-term than ALEC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALEC’s TA Score shows that 5 TA indicator(s) are bullish while RGNX’s TA Score has 3 bullish TA indicator(s).

  • ALEC’s TA Score: 5 bullish, 3 bearish.
  • RGNX’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ALEC is a better buy in the short-term than RGNX.

Price Growth

ALEC (@Biotechnology) experienced а -0.35% price change this week, while RGNX (@Biotechnology) price change was -7.13% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +11.36%. For the same industry, the average monthly price growth was +17.11%, and the average quarterly price growth was +3.22%.

Reported Earning Dates

ALEC is expected to report earnings on Jul 31, 2025.

RGNX is expected to report earnings on Jul 30, 2025.

Industries' Descriptions

@Biotechnology (+11.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($418M) has a higher market cap than ALEC($155M). RGNX YTD gains are higher at: 7.762 vs. ALEC (-25.132). ALEC has higher annual earnings (EBITDA): -137.59M vs. RGNX (-198.23M). ALEC has more cash in the bank: 355M vs. RGNX (235M). ALEC has less debt than RGNX: ALEC (41M) vs RGNX (82M). ALEC has higher revenues than RGNX: ALEC (88.3M) vs RGNX (83.3M).
ALECRGNXALEC / RGNX
Capitalization155M418M37%
EBITDA-137.59M-198.23M69%
Gain YTD-25.1327.762-324%
P/E RatioN/AN/A-
Revenue88.3M83.3M106%
Total Cash355M235M151%
Total Debt41M82M50%
FUNDAMENTALS RATINGS
ALEC vs RGNX: Fundamental Ratings
ALEC
RGNX
OUTLOOK RATING
1..100
1961
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
73
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
5544
P/E GROWTH RATING
1..100
9319
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALEC's Valuation (51) in the Biotechnology industry is in the same range as RGNX (73). This means that ALEC’s stock grew similarly to RGNX’s over the last 12 months.

ALEC's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that ALEC’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (95) in the Biotechnology industry is in the same range as ALEC (100). This means that RGNX’s stock grew similarly to ALEC’s over the last 12 months.

RGNX's Price Growth Rating (44) in the Biotechnology industry is in the same range as ALEC (55). This means that RGNX’s stock grew similarly to ALEC’s over the last 12 months.

RGNX's P/E Growth Rating (19) in the Biotechnology industry is significantly better than the same rating for ALEC (93). This means that RGNX’s stock grew significantly faster than ALEC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALECRGNX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 18 days ago
75%
Declines
ODDS (%)
Bearish Trend 24 days ago
88%
Bearish Trend 2 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
63%
View a ticker or compare two or three
Interact to see
Advertisement
ALEC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NGRRX33.25N/A
N/A
Nuveen International Value I
AWACX22.42N/A
N/A
AB Wealth Appreciation Strategy C
AZNCX9.54N/A
N/A
Virtus Income & Growth C
LIDOX9.50N/A
N/A
Lord Abbett International Value F3
RPMYX12.09N/A
N/A
Reinhart International PMV Advisor